A recent study sought to identify possible differences in subcortical structures between patients who have migraine with aura (MwA) and healthy subjects, and also to determine the correlations between the characteristics of migraine aura and the volumes of subcortical structures.
A recent study sought to identify possible differences in subcortical structures between patients who have migraine with aura (MwA) and healthy subjects, and also to determine the correlations between the characteristics of migraine aura and the volumes of subcortical structures.
Various features of the cerebral cortex and white matter have been extensively investigated in MwA, but the morphological characteristics of subcortical structures have been largely neglected.
Aura in migraine affects about 20% to 30% of patients; it is a phenomenon whose manifestations coincide with a wave of cortical spreading depolarization/depression (CSD) through the cerebral cortex and/or through the 3 different types of white matter nerve fibers (associative, commissural, and projective). Imaging studies have described multiple changes in the migraineur brain.
A few studies have investigated the role of subcortical structures in the pathophysiology of migraine, revealing decreased volumes of the left caudate, putamen, right nucleus accumbens, and striatum; in addition, it was found that the basal ganglia play a significant role in the pathophysiology of pain in episodic migraine.
However, previous studies did not examine the role of subcortical structures in the pathophysiology of MwA, nor did they look at the volume and shape abnormalities in distinct subcortical structures. Therefore, the aim of this study was to compare the volumes of subcortical structures between patients with MwA and healthy subjects, using advanced structural neuroimaging techniques, as well as the correlations between the characteristics of MwA and the volumes of subcortical structures.
Thirty-two patients with MwA were matched by age and sex to 32 healthy subjects. Regional subcortical brain volumes were automatically calculated using the FSL/FMRIB Image Registration and Segmentation Tool software. A general linear model analysis was used to investigate differences in the volume of subcortical structures between the 2 groups. A partial correlation test was used to assess correlations between the volume of subcortical structures and characteristics of patients with MwA.
The volumes of the right globus pallidus, left globus pallidus, and left putamen were significantly smaller in the brains of patients with MwA than in those without: mean (SD): 1427 (135) mm3 versus 1557 (136) mm3 (P <.001); 1436 (126) mm3 versus 1550 (139) mm3 (P = .001); and 4235 (437) mm3 versus 4522 (412) mm3 (P = .006); respectively. There were no significant relationships between subcortical structures and clinical parameters.
These findings suggest that both the globus pallidi and left putamen play significant roles in the pathophysiology of the MwA. Future studies should determine the cause-and-effect relationships, since these could not be found in this study due to its cross-sectional design.
Reference
Petrusic I, Dakovic M, Zidverc-Trajkovic J. Subcortical volume changes in migraine with aura [published online Jul 15, 2019]. J Clin Neurol. doi: 10.3988/jcn.2019.15.4.448.
Prior Authorization Requirements for Calcitonin Gene-Related Peptide Antagonists
April 20th 2023This quantitative and qualitative analysis highlights differences in prior authorization requirements for migraine drugs from nearly 50 managed care organizations and summarizes broad types of criteria used.
Read More
Update on Migraine Patient Care Challenges During the Pandemic
October 5th 2021Migraines plague some 35 million Americans, the majority of them women in their 30s and 40s, and disabling pain and symptoms are linked to lost productivity at work, school, and home. On this episode of Managed Care Cast, we bring you an excerpt of an interview with a headache specialist about the extra challenges for patients and providers during the pandemic.
Listen
CGRP Inhibitors: A Promising New Class of Drugs for Migraine
November 14th 2018This fall, The American Journal of Managed Care® convened a panel of experts on migraine to discuss calcitonin gene-related peptide (CGRP) inhibitors, an emerging therapy for the condition, which affects 39 million people in the United States.
Listen